Efficacy and safety of high-flow oxygen therapy using an asymmetric nasal cannula for postextubation respiratory failure in patients at risk of reintubation.

Efficacy and safety of high-flow oxygen therapy using an asymmetric nasal cannula for postextubation respiratory failure in patients at risk of reintubation. - Efficacy and safety of high-flow oxygen therapy using an asymmetric nasal cannula for postextubation respiratory failure in patients at risk of reintubation.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs072250014

Enrollment

Registered

2025-04-30

Start date

2025-04-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Failure

Interventions

(1) After obtaining study consent, randomization will be performed according to a web-based blocked random sequence to allocate the patients into 2 groups: (i) S-HFNC to A-HFNC, (ii) A-HFNC to S-HFNC

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients admitted to an intensive care unit (ICU) who are intubated due to a medical condition and have at least one risk item for reintubation after extubation. (2) Patients who are 18 years of age or older at the time of consent. (3) Patients who have received a thorough explanation of their participation in this study, and who have obtained written consent from the patient or the patient's surrogate, based on sufficient understanding.

Exclusion criteria

Exclusion criteria: (1) Patients intubated for respiratory management associated with surgical procedures (surgical procedures, traumatic diseases, poisoning, burns, etc.) (2) Patients receiving continuous oxygen administration via nasal cannula (home oxygen therapy (3) Patients with a history of pneumothorax (4) Patients without spontaneous respiration (5) Patients with obstruction of the nasal passages due to abnormalities of the nasal mucosa, etc. (6) Patients with a history of CSF leakage or head injury (7) Patients with cribriform plate abnormalities (8) Patients with pneumoencephalopathy, pneumothorax, cystic lung disease, or pathological hypotension (9) Patients with upper airway bypass (10) Patients participating in clinical trials or other clinical studies (11) Other patients who are deemed inappropriate as research subjects by the principal investigators and subinvestigators.

Design outcomes

Primary

Measure	Time frame
Improvement of respiratory workload: tidal volume (derived from deltaZ measured by EIT)	—

Secondary

Measure	Time frame
1) PEEP augmentation effect:total delta EELZ, ventral delta EELZ, dorsal delta EELZ, GI index 2) Improvement of respiratory workload other than tidal volume:ventral tidal volume, dorsal tidal volume,minute volume (=tidal volume x respiratory rate), corrected minute volume(=minute volume x PaCO2/40) 3) ROX index, Vital signs 4) PaCO2, PaO2/FIO2 5) Comfort 6) Dyspnea	—

Contacts

Public ContactOsamu Tasaki

Nagasaki University Hospital

tasaki-o@nagasaki-u.ac.jp+81-95-819-7765

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026